- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Chiasma Inc.
Headquarters: Needham, MA, United States
Website: N/A
Year Founded: 2001
Status: Acquired
BioCentury | Jun 26, 2023
Management Tracks
Charl van Zyl to succeed Dunsire at Lundbeck
Plus: Raj Kannan named CEO at I-Mab, and updates from uniQure, Immodulon, Ichnos and more
BioCentury | Jan 9, 2023
Deals
Chiesi bolsters rare disease portfolio via $1.3B Amryt buyout
Italian pharma becomes latest home for therapies Amryt obtained in 2019 merger with Aegerion; deal has CVRs tied to rare skin disease therapy
BioCentury | Jan 3, 2022
Management Tracks
Robertson becomes Opthea’s first CCO
Plus: 4D Pharma, NeuShen, Mind, PolyPid and Biosion
BioCentury | Dec 21, 2021
Management Tracks
Founder Zang returns to CEO role at I-Mab
Plus: Ho out as CRISPR’s head of R&D, Pfizer’s Hicks named Intellia’ CBO and more
BioCentury | Dec 17, 2021
Management Tracks
Jonsson becomes COO at Nordic Nanovector
Plus: Aerie, Bio-Rad, Affinivax, Neogene, Orna and more
BioCentury | Sep 29, 2021
Management Tracks
Rawat becomes president, CBO at Fusion
Plus: Sporos, Ajax, Nanocan and NeuroSense
BioCentury | Aug 27, 2021
Management Tracks
Pfizer names McKinsey vet Malik to succeed Young
Plus: Lonza, Renovacor, Lilly, Adamis, NeoImmuneTech and more
BioCentury | May 6, 2021
Deals
May 5 Quick Takes: Perlmutter joining Eikon as VCs pour in $148M; plus venture money for Foresite’s Esker, BridGene, Isolere and more
Months after he retired from Merck & Co. Inc. (NYSE:MRK), newly hired CEO Roger Perlmutter will lead Eikon Therapeutics Inc. as it seeks to "industrialize" fluorescent microscopy
BioCentury | Jan 21, 2021
Management Tracks
MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar, and Imara
Dynavax Technologies Corp. (NASDAQ:DVAX) hired Kelly MacDonald as SVP and CFO, effective March 1. She succeeds CFO Michael Ostrach, who is retiring after 14 years and will remain with the vaccine
BioCentury | Oct 2, 2020
Management Tracks
Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more
AI and machine learning company insitro appointed Roger Perlmutter, EVP and president of Merck Research Laboratories, as its first independent board member. Kiran Mazumdar-Shaw has joined the
Items per page:
1 - 10 of 64